Background/Objectives: The present study evaluates predictive implications of the pretherapeutic Fibrinogen–Albumin-Ratio Index (FARI) in high-grade serous ovarian cancer (HGSOC) patients undergoing primary cytoreductive surgery. Methods: This retrospective study included 161 patients with HGSOC International Federation of Gynecology and Obstetrics (FIGO) stage ≥ IIb, who underwent primary cytoreductive surgery followed by platinum-based chemotherapy. Associations between the FARI and complete tumor resection status were described by receiver operating characteristics, and binary logistic regression models were fitted. Results: Higher preoperative FARI values correlated with higher ascites volumes (r = 0.371,p< 0.001), and higher CA125 levels (r = 0.271,p= 0.001). A high FARI cut at its median (≥11.06) was associated with lower rates of complete tumor resection (OR 3.13, 95% CI [1.63–6.05],p= 0.001), and retrained its predictive value in a multivariable model independent of ascites volumes, CA125 levels, FIGO stage, and Charlson Comorbidity Index (CCI). Conclusions: The FARI appears to act as a surrogate for higher intra-abdominal tumor load. After clinical validation, FARI could serve as a readily available serologic biomarker to complement preoperative patient assessment, helping to identify patients who are likely to achieve complete tumor resection during primary cytoreductive surgery.
背景/目的：本研究评估治疗前纤维蛋白原-白蛋白比值指数（FARI）对接受初次肿瘤细胞减灭术的高级别浆液性卵巢癌（HGSOC）患者的预测意义。方法：这项回顾性研究纳入了161例国际妇产科联盟（FIGO）分期≥IIb期的HGSOC患者，所有患者均接受初次肿瘤减灭术及后续铂类化疗。通过受试者工作特征曲线描述FARI与肿瘤完全切除状态的相关性，并建立二元逻辑回归模型。结果：较高的术前FARI值与较多的腹水量（r=0.371，p<0.001）及较高的CA125水平（r=0.271，p=0.001）呈正相关。以中位数（≥11.06）为界值的高FARI与较低的肿瘤完全切除率相关（OR 3.13，95% CI [1.63–6.05]，p=0.001），在多变量模型中，即使调整腹水量、CA125水平、FIGO分期和查尔森合并症指数（CCI）后，其预测价值依然保持。结论：FARI可作为腹腔内肿瘤负荷较高的替代指标。经临床验证后，FARI有望成为一种易于获取的血清学标志物，用于补充术前患者评估，帮助识别在初次肿瘤细胞减灭术中可能实现肿瘤完全切除的患者。
肿瘤(癌症)患者之家